222 related articles for article (PubMed ID: 37131698)
1. An
Atanasoff KE; Brambilla L; Adelsberg DC; Kowdle S; Stevens CS; Hung CT; Fu Y; Lim R; Tran L; Allen R; Andrew Duty J; Bajic G; Lee B; Tortorella D
bioRxiv; 2023 Apr; ():. PubMed ID: 37131698
[TBL] [Abstract][Full Text] [Related]
2. An
Atanasoff KE; Brambilla L; Adelsberg DC; Kowdle S; Stevens CS; Slamanig S; Hung C-T; Fu Y; Lim R; Tran L; Allen R; Sun W; Duty JA; Bajic G; Lee B; Tortorella D
mBio; 2024 Jan; 15(1):e0247723. PubMed ID: 38054729
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
[TBL] [Abstract][Full Text] [Related]
4. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
5. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
6. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
9. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice.
Lu RM; Liang KH; Chiang HL; Hsu FF; Lin HT; Chen WY; Ke FY; Kumari M; Chou YC; Tao MH; Yi-Ling Lin ; Wu HC
Heliyon; 2023 May; 9(5):e15587. PubMed ID: 37090428
[TBL] [Abstract][Full Text] [Related]
11. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
12. Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins.
Kumar S; Dasgupta S; Sajadi MM; Snyder GA; DeVico AL; Ray K
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543772
[TBL] [Abstract][Full Text] [Related]
13. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
14. Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment.
Patterson LD; Dubansky BD; Dubansky BH; Stone S; Kumar M; Rice CD
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257764
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
[TBL] [Abstract][Full Text] [Related]
16. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.
Maghsood F; Amiri MM; Zarnani AH; Salimi V; Kardar GA; Khoshnoodi J; Mobini M; Ahmadi Zare H; Ghaderi A; Jeddi-Tehrani M; Schmidt S; Laumond G; Moog C; Shokri F
Front Med (Lausanne); 2022; 9():973036. PubMed ID: 36148457
[TBL] [Abstract][Full Text] [Related]
17. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.
Xu S; Wang Y; Wang Y; Zhang C; Hong Q; Gu C; Xu R; Wang T; Yang Y; Zang J; Zhou Y; Li Z; Liu Q; Zhou B; Bai L; Zhu Y; Deng Q; Wang H; Lavillette D; Wong G; Xie Y; Cong Y; Huang Z
Emerg Microbes Infect; 2022 Dec; 11(1):351-367. PubMed ID: 34964428
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2.
Chu X; Ding X; Yang Y; Lu Y; Li T; Gao Y; Zheng L; Xiao H; Yang T; Cheng H; Huang H; Liu Y; Lou Y; Wu C; Chen Y; Yang H; Ji X; Guo H
Biochem Biophys Res Commun; 2023 Jun; 660():43-49. PubMed ID: 37062240
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
20. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
